Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VNRX 
Volitionrx Ltd (VNRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VNRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.91
1 Year Target Price $2.91
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.02% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.28M USD | Price to earnings Ratio - | 1Y Target Price 2.91 |
Price to earnings Ratio - | 1Y Target Price 2.91 | ||
Volume (30-day avg) 6 | Beta 1.27 | 52 Weeks Range 0.40 - 0.94 | Updated Date 10/17/2025 |
52 Weeks Range 0.40 - 0.94 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1548.56% |
Management Effectiveness
Return on Assets (TTM) -134.74% | Return on Equity (TTM) -730.06% |
Valuation
Trailing PE - | Forward PE 20.83 | Enterprise Value 75968068 | Price to Sales(TTM) 40.39 |
Enterprise Value 75968068 | Price to Sales(TTM) 40.39 | ||
Enterprise Value to Revenue 57.58 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 119145421 | Shares Floating 77304082 |
Shares Outstanding 119145421 | Shares Floating 77304082 | ||
Percent Insiders 16.82 | Percent Institutions 20.79 |
Upturn AI SWOT
Volitionrx Ltd
Company Overview
History and Background
VolitionRx Limited is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Founded in 2010, the company has focused on Nucleosomicsu2122, its platform which identifies and measures circulating nucleosomes, to develop its Nu.Qu00ae platform.
Core Business Areas
- Cancer Diagnostics: Focuses on developing blood-based diagnostic tests for various cancers using its Nu.Qu00ae platform.
- Nu.Qu00ae Platform Development: Research and development of the Nu.Qu00ae platform, which targets circulating nucleosomes for disease detection.
Leadership and Structure
Cameron Reynolds is the Chief Executive Officer. The company operates with a research and development-focused organizational structure, emphasizing scientific expertise and regulatory compliance.
Top Products and Market Share
Key Offerings
- Nu.Qu00ae Platform: VolitionRx's primary offering is its Nu.Qu00ae platform, a blood-based cancer diagnostic platform. Market share data is still developing. Competitors include companies developing liquid biopsy technologies, such as Exact Sciences (EXAS) and Guardant Health (GH).
- Nu.Qu00ae Veterinary: A test for the detection of cancer in animals, particularly dogs. Market share is small and growing in the veterinary space. Competitors include Antech Diagnostics and IDEXX Laboratories.
Market Dynamics
Industry Overview
The cancer diagnostics industry is experiencing rapid growth, driven by advancements in liquid biopsy technologies and increasing demand for non-invasive diagnostic tools. The market is characterized by intense competition and regulatory scrutiny.
Positioning
VolitionRx aims to position itself as a leader in blood-based cancer diagnostics using its unique Nu.Qu00ae platform. Its competitive advantage lies in the potential for simple, cost-effective tests with broad applicability.
Total Addressable Market (TAM)
The TAM for cancer diagnostics is estimated to be in the tens of billions of dollars. VolitionRx is positioned to capture a portion of this market with its Nu.Qu00ae platform, initially targeting specific cancer types.
Upturn SWOT Analysis
Strengths
- Proprietary Nu.Qu00ae platform
- Potential for cost-effective and non-invasive cancer diagnostics
- Strong scientific team
- Early-stage validation of technology
Weaknesses
- Limited commercialization to date
- Dependence on regulatory approvals
- Requires more study for human medicine
- Significant operating losses
Opportunities
- Expanding applications of Nu.Qu00ae platform to other diseases
- Strategic partnerships with diagnostic companies
- Increasing adoption of liquid biopsy technologies
- FDA approval for human medical testing
Threats
- Competition from established diagnostic companies
- Regulatory hurdles and changing guidelines
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- EXAS
- GH
- IDXX
- AN
- BRLI
Competitive Landscape
VolitionRx competes with larger, more established diagnostic companies. Its advantage lies in its novel Nu.Qu00ae platform, but it faces challenges in commercialization and market penetration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by R&D progress and collaborations rather than product revenue.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of Nu.Qu00ae-based tests. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials, regulatory submissions, and strategic partnerships.
Summary
VolitionRx is a development-stage company with a promising Nu.Qu00ae platform for cancer diagnostics. It faces challenges in commercialization, regulatory approval, and competition. Successful clinical trials and strategic partnerships are crucial for its future growth. Financially, the company continues to seek funding to support operations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- VolitionRx Ltd SEC Filings (10-K, 10-Q), Press Releases, Investor Presentations, Industry Reports, Yahoo Finance, Google Finance
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Volitionrx Ltd
Exchange NYSE MKT | Headquaters Henderson, NV, United States | ||
IPO Launch date 2007-04-25 | Founder, CEO, President & Director Mr. Cameron Reynolds MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 70 | Website https://volition.com |
Full time employees 70 | Website https://volition.com | ||
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.